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Objectives To characterize the clinical course of mucopolysaccharidosis type IIIA (MPS IIIA), and identify poten-
tial endpoints for future treatment trials.
Study design Children with a confirmed diagnosis of MPS IIIA, functioning above a developmental age of 1 year,
were followed for up to 2 years. Cognitive status and brain atrophy were assessed by standardized tests and volu-
metric magnetic resonance imaging, respectively. Liver and spleen volumes and cerebrospinal fluid and urine
biomarker levels were measured.
Results Twenty-five children, from 1.1 to 18.4 years old, were enrolled, and 24 followed for at least 12 months. 19
exhibited a rapidly progressing (RP) form of MPS IIIA, and 5, a more slowly progressing form. Children with RP pla-
teaued in development by 30 months, followed by rapid regression after 40-50 months. In patients with RP, cogni-
tive developmental quotients showed consistent steep declines associated with progressive cortical gray matter
atrophy. Children with slowly progressing had a similar but more prolonged course. Liver and spleen volumes
were approximately double normal size, and cerebrospinal fluid and urine heparin sulfate levels were elevated
and relatively constant over time.
Conclusion Developmental quotient and cortical gray matter volume are sensitive markers of disease progres-
sion in MPS IIIA, and may have utility as clinical endpoints in treatment trials. For optimal outcomes, treatment
may need to be instituted in children before the onset of steep cognitive decline and brain atrophy. (J Pediatr
2016;170:278-87).
Trial registration ClinicalTrials.gov: NCT01047306.From the 1Department of Pediatrics, and 2Division of
Biostatistics, University of Minnesota, Minneapolis, MN;
and 3Shire, Lexington, MA
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his longitudinal observational study of the rare lysosomal storage disease
mucopolysaccharidosis type IIIA (MPS IIIA; also known as Sanfilippo
syndrome type A) was conducted to gather standardized data on the nat-
ural course of this neurodegenerative disease over 2 years, to assess brain function
and structure, and to identify potential endpoints for future treatment trials.
MPS IIIA is a progressive lethal disease caused by deficiency of lysosomal N-
sulphoglucosamine sulphohydrolase (SGSH), which degrades heparan sulfate
(HS). This autosomal recessive disorder has an incidence of 0.27-1.89 per
100 000 births.1 MPS IIIA is the least rare of 4 subtypes (types A, B, C, and D),
each of which results from an enzyme deficiency in the catabolic pathway for
HS. SGSH is localized to 17q25.3, with more than 100 mutations described2,3
associated with either rapid or slower progression.1,3 Developmental slowing be-
gins in the second year of life, followed by cognitive decline and behavioral dis-
turbances.1,3 No therapy is known to modify disease.
A challenge in monitoring new treatments is the lack of knowledge about
the rate and variability of clinical disease progression. Although retrospective
studies1,3-5 and studies of the behavioral phenotype6,7 have been reported,outside of the submitted work from Shire. I.N. received
investigator-initiated grants from Shire; An Open-La-
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Volume 170  March 2016prospective studies examining the sequence and timing of
cognitive decline and symptom emergence are lacking. We
hypothesize that cognitive, imaging, and biomarker
changes over a 2-year time period will be associated with
disease stage and severity.Methods
Twenty-five patients with MPS IIIA were recruited to this
single-center study. Inclusion criteria were: (1) confirmed
diagnosis of MPS IIIA; (2) calendar age $1 year; and (3)
developmental age$1 year as assessed by the Vineland Adap-
tive Behavior Scales, Second Edition (VABS-II).8 Exclusion
criteria were: (1) history of hematopoietic cell transplanta-
tion; (2) presence of significant non–MPS IIIA-related cen-
tral nervous system impairment; and (3) vision or hearing
impairment sufficient to preclude developmental assessment.
An Ethics Committee–approved informed consent form was
signed by a parent/guardian of each subject.
Assessments were performed at baseline, 6 months, 1 year,
and2 years during a 3-dayvisit.Developmental testingwas con-
ducted on the day before any procedures requiring anesthesia.
Cerebrospinal fluid (CSF) opening pressure was measured
via routine manometry at each lumbar puncture. SGSH
mutational analysis was performed for each patient.
Adaptive behavior was measured by parent report using
the VABS-II. A neurocognitive assessment was performed
for each patient. One of 2 standard instruments, the Bayley
Scales of Infant and Toddler Development, Third Edition
(BSID-III)9 or the Kaufman Assessment Battery for Children,
Second Edition (KABC-II),10 was used based on anticipated
age and ability range. Age-equivalent scores (AEqs) were
generated from published normative data,9,10 and a develop-
mental quotient (DQ) was derived by dividing the AEq by
chronological age and then multiplying by 100. This accepted
approach avoids the “floor” effects of standardized scores
applied to severely cognitively impaired children.11-13 Either
the BSID-III or the KABC-II nonverbal scale was chosen for
all of each child’s visits according to a specific algorithm as
described previously.14
The Four-Point Scoring System (FPSS),4 an MPS III–spe-
cific parent-completed disability questionnaire that rates
motor, expressive language, and cognitive function on a 3-
point scale (normal, 3; beginning regression, 2; severe regres-
sion, 1; lost skill, 0), was administered. A total disability score
was then calculated as the average of these 3 scores.
The Children’s Sleep Habits Questionnaire was completed
by the parents.15 Based on our experience with patients with
MPS IIIA, we added 3 additional items to the original ques-
tionnaire: disruptive behavior at night, dangerous behavior
at night, and sleeping during the day.
Magnetic resonance imaging (MRI) of the head was
performed on a 3-T Siemens Trio scanner (Siemens,
Erlangen, Germany) with a 12-channel radiofrequency head
coil. The protocol included 3-dimensional, T1-weighted,
magnetization-prepared rapid acquisition with gradient-echo sequence. Volumetric analysis of gray and white matter
and CSF ventricles was performed using FreeSurfer Image
Analysis Suite version 5.1 (Martinos Center, Harvard Univer-
sity, Boston, Massachusetts).16 The resulting segmentations
were visually inspected for mislabeling of anatomy and
manually adjusted if necessary.
Liver and spleen volumetric measurements were obtained
byMRI, using the same instrument as used for the headMRI.
Liver and spleen volumes were normalized to body surface
area and weight, respectively, as described previously.17,18
Biomarker analyses included urinary glycosaminoglycan
(GAG) concentration, HS in CSF, and total tau (T-tau) and
phospho-tau (p-tau) proteins in CSF. The urinary GAG con-
centration was determined by a 1,9-dimethyl-methylene blue
dye binding assay using the Blyscan assay kit (Biocolor Ltd,
Carrickfergus, Northern Ireland, United Kingdom), and was
reported relative to creatinine concentration (mg GAG/
mmol creatinine). The level of totalHS in CSFwas determined
by liquid chromatography–tandem mass spectrometry (LC-
MS/MS). HS in the CSF was first extracted using an anion-
exchange resin and thendigestedby a combinationof enzymes,
including heparinase I, II, and III. The resultant HS disaccha-
rides were labeled with 12C-4-N-butylaniline by reductive
amination and then analyzed by LC-MS/MS. The disaccha-
rides were quantified based on a calibration curve generated
using 6 commercially available disaccharide standards that
are the most abundant in human CSF HS.19 CSF levels of T-
tau and p-tau proteins were measured by immunoassay.
Control patient data were provided by the University of
Innsbruck. These patients and parents provided consent,
and the samples were anonymized.
Descriptive statistics were summarized overall and by sub-
groups described below. Data are reported as mean SD for
continuous covariates and as frequency and percentage for
categorical variables. Cortex volumes at later visits could
not be obtained for 5 patients owing to extreme atrophy
and so were imputed based on each patient’s previous trajec-
tory to diminish bias from missing data. Sensitivity analyses
for the imputation were conducted as well. The curved mean
developmental trajectory was based on local polynomial
smoothing.20 Longitudinal associations were estimated with
generalized estimating equations and robust variance esti-
mates for 95% CIs and P values to account for the correlated
nature of longitudinal measurements. All analyses were con-
ducted using R version 3.0.1.21Results
The cohort comprised 16 males and 9 females, with a median
age of 4.8 years (range, 1.1-18.4 years) at enrollment between
February 2010 and May 2011. One patient dropped out after
the baseline visit for personal reasons; 24 patients were fol-
lowed for 12 months, and 20 were followed for 24 months.
Six sets of siblings were enrolled, including 1 set of dizygotic
twins. The youngest 2 children were identified because of a
diagnosis in an older sibling.279
Table I. Genetic and demographic data for study subjects






















1 R245H L12P Severe/new22,23 RP Female 42 79 14/10/NA 18/11/NA 2.3/1.3/1.3
2 N389S N389S New/new RP Male 34 38 21/16/14 55/31/21 2.3/2.0/2.0
4 R245H R245H Severe/severe3,22,23 RP Male 24 28 25/27/30 89/66/53 3.0/2.3/1.7
5† S66W Q380R Severe/severe3,22,24 RP Male 27 29 23/23/23 79/53/40 1.7/2.0/2.0
6† S66W Q380R Severe/severe3,22,24 RP Male 28 29 22/23/18 76/53/31 1.7/2.0/2.0
7 S66W R245H Severe/severe3,22,23 RP Male 65 95 8/8/8 8/7/7 1.0/1.0/1.0
9z R245H R433Q Severe/severe22,23,25,26 RP Female 50 67 27/24/22 40/30/23 1.7/2.0/1.7
10z R245H R433Q Severe/severe22,23,25,26 RP Male 23 40 27/27/27 68/52/40 2.0/2.0/2.0
11 R245H R377H Severe/severe2,22-24 RP Male 52 88 12/12/13 14/12/11 2.0/1.7/1.7
12z S66W M376R Severe/new3,22 RP Female 56 80 9/8/NA 11/9/NA 2.0/1.3/1.3
13z S66W M376R Severe/new3,22 RP Male 19 43 25/17/9 58/30/13 2.0/2.0/1.3
15z E447K int7 +1G>C Severe/new2,22 RP Male 48 51 14/7/14 27/11/18 1.7/1.3/1.3
16z E447K int7 +1G>C Severe/new2,22 RP Male 9 13 11/16/16 85/62/41 3.0/2.3/2.0
19 1272del 11bp 1272del 11bp Severe/severe2,22 RP Female 36 37 25/28/27 68/57/44 2.3/2.0/2.0
21 c.197C>G c.734G>A Severe/severe3,22,23 RP Female 29 50 25/15/10 50/24/14 1.7/2.0/1.7
23 c.197C>G c.1080delC Severe/severe3,22,27,28 RP Male 29 45 35/28/NA 78/47/NA 1.7/2.0/2.3
24z R74C R74C Severe/severe2,28,29 RP Female 18 22 20/27/31 91/82/67 3.0/2.7/2.3
25z R74C R74C Severe/severe2,28,29 RP Male 52 57 17/13/13 30/19/16 1.7/1.7/1.7
22x R74C P293S Severe/severe2,28-30 RP Male 99 105 10/11/11 10/9/8 1.3/1.3/1.3
3 R245H L59F Severe/new22,23 SP Male 77 81 46/50/55* 57/53/50 2.0/2.3/2.3
14 P293S S298P Severe/mild3,29,30 SP Female 128 201 45/51/NA* 22/24/NA 2.3/2.0/2.0
17z 1079delC A311D Severe/new24,28 SP Male 127 132 28/27/27 21/19/17 1.7/2.0/2.0
18z 1079delC A311D Severe/new24,28 SP Female 150 155 61/70/69* 39/42/38 2.0/2.3/2.3
20 P293S S298P Severe/mild3,29,30 SP Female 187 220 6/6/5 3/3/2 1.0/1.0/1.0
NA, not administered; patient untestable.
*6-mo cognitive data not shown.
†Dizygotic twins.
zSibling pairs.
xPatient diagnosed after age 6 y; diagnosed with autism at age 3 y, classified as severe/RP.
THE JOURNAL OF PEDIATRICS  www.jpeds.com Volume 170The patients were sorted post hoc into one of 2 groups,
rapidly progressing (RP) or slowly progressing (SP), based on
diagnosis before (RP) or after (SP) age 6 years, reportedly a reli-
able indicator of disease severity,1 and/or known severe geno-
type. All analyses were conducted separately in these 2 groups.
Six novel mutations were discovered (Table I). Thirteen of
the 19 patients the RP group were either homozygous or
compound heterozygous for known severe mutations; 5
patients were compound heterozygous for a known mutation
associated with severe disease and 1 of 3 novel mutations, and
1 patient was homozygous for a novel mutation, N389S. All
of the patients in the SP group were compound heterozygous
for mutations; 2 patients had a known severe mutation
associated with S298P, previously reported to confer a
relatively mild phenotype.29 Three patients in the SP group,
including 1 pair of siblings, had a severe mutation in
association with 1 of 2 new mutations, L59F or A311D. Thus,
these 2 new mutations are associated with SP disease.
Neurocognitive Assessment
Two experienced psychometrists tested 21 patients (19 RP
and 2 SP) with the BSID-III and 3 patients (all SP) with the
KABC-II (Table I). Based on AEqs, the 3 youngest
children, all aged <28 months, continued to acquire skills,
as reflected in an upward trajectory (Figure 1, A). A
slowing of development between 36 and 40 months and a
loss of skills after 48 months was noted in the RP group.
After 66 months, the cognitive decline appeared to reach a280nadir. The 5 patients in the SP group displayed no
consistent trends over time.
Based on the DQ, patients in the RP group showed a dra-
matic decline over time, estimated at 9.8 points/year (95%
CI, 11.8 to 7.7; P < .001) (Figure 1, B). This was most
notable up to age 6, where the decline was 14.6 points/
year (95% CI, 17.5 to 11.8). In comparison, the DQ
decline in the SP group was 3.7 points/year (95% CI,
5.0 to 2.4; P = .012).
Adaptive Behavior
AEqs on the VABS-II indicated continuing acquisition of
skills in the RP group before age 50 months, with subsequent
loss of skills (Figure 2). The scores of patients with SP were
notably different, with no clear trends evident.
Disability
FPSS total disability scores were closely associated with DQ at
the high and low ends, but showed a lack of association of DQ
with FPSS scores in themiddle of the range (Table I). The FPSS
was able to correctly classify some of the least-impaired
children (n = 4) with a score of 2.7 or 3.0 (mean DQ, 87;
range, 82-91). The FPSS was also sensitive to the most-
impaired children (score of 1 or 1.3) (mean DQ, 11; range, 2-
31) but misclassified a few; however, the FPSS was insensitive
in the mid-range, with many overlapping DQ scores at FPSS
scores of 1.7 (mean DQ, 37; range, 11-79), 2 (mean DQ, 44;
range, 11-79), and 2.3 (mean DQ, 55; range, 18-82).Shapiro et al
Figure 1. A, Trajectory of cognitive growth by age for the RP and SP groups compared with published normative growth data
(gray-shaded area), with a ceiling at 42months. The BSID-III was administered to all patients in the RP group and to 2 of 5 patients
in the SP group. The KABC-II was administered to the other 3 patients in the SP group, who had a baseline age equivalent of
>42 months. The red line indicates the growth trajectory for the RP group only. B, Change in DQ (100  age equivalent/chro-
nological age) by age for the RP and SP groups.
March 2016 ORIGINAL ARTICLES
A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA 281
Figure 2. Developmental growth trajectory of mean AEqs in the RP and SP groups for composite score compared with normal
published data for the VABS-II. The initial assessment was based on the survey interview form with parents, and subsequent
assessments were based on the parent rating form.
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Although many sleep problems were reported, no pattern or
change over time was observed (data not shown). The data
were insensitive for use in a clinical trial even as a secondary
marker.
Imaging
Volumetric analysis was completed for all but 10 MRI scans.
Two children, aged <24 months, exhibited a lack of gray mat-
ter and white matter differentiation, thought to reflect imma-
turity of myelination,31 which precluded volumetric
assessment at baseline and at 6 months for 1 child and at
baseline for the other child. In 5 children, progressive atro-
phic changes resulted in analytic failure, even with manual
adjustment, noted at the 24-month visit. For these patients,
values were imputed from the slope of previous visits. In 1
child with a ventriculoperitoneal shunt, artifact precluded
volumetric analysis at all 4 assessment points.
The trajectories of cortical gray matter volumes over time
in the RP and SP groups are shown in Figure 3, A. A striking
decline was seen in patients in the RP group, consistent at
41.1 mL/year (95% CI, 52.7 to 29.4; P < .001),
compared with 26.4 mL/year (95% CI, 37.4 to 15.4;
P < .001) in the SP group. The estimates for the RP group
were not significantly different when imputed values were
not used.282In the youngest patients, white matter volume exhibited an
upward trajectory until age40months, with subsequent de-
clines evident in most children in the RP group. Patients in
the SP group showed little or no change (Figure 4, A;
available at www.jpeds.com).
Ventricular volumes increased in all age groups and in
both the RP and SP groups, although with a steeper upward
trajectory in the RP group (Figure 5; available at www.jpeds.
com).
The association between a decline in DQ and gray matter
volume over all visits is graphed in Figure 3, B. No
association between DQ and white matter volume was
observed (Figure 4, B).
Liver and spleen volumes were increased at baseline in
most patients across age groups, with an approximate
doubling of organ volume compared with expected values
(Figure 6; available at www.jpeds.com).17,18 No trends were
apparent over the observation period (data not shown).
Biomarkers
Total urine GAG level remained elevated in all patients rela-
tive to control values (Figure 7, A). The apparent overall
decline with increasing age confounded interpretation of
lower levels in the patients in the SP group. Similarly, CSF
HS levels were elevated in all patients compared with
controls (Table II; available at www.jpeds.com), withShapiro et al
Figure 3. A, Change in gray matter volume for the RP and SP groups by age. B, Association of decline in DQ with gray matter
volume for the RP and SP groups. Open circles indicate the imputed values, which are connected with dotted lines (values
imputed from slope of previous visits) for 4 patients at the 24-month visit only and for 1 patient at both the 12-month and 24-
month visits.
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Figure 7. A,Change in urine GAGs by age for the RP and SP groups. Upper limit of normal values were taken fromNaimy et al,19
who provided values in 2-year increments from 0 to 14 years and older with the step at the end of each increment. B,Changes in
CSF HS level by age for the RP and SP groups. Control values are listed in Table II.
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with the SP group (Figure 7, B). Neither CSF HS nor urine
GAG levels exhibited within-patient time-dependent284increases associated with disease progression. CSF HS levels
were strikingly similar in 4 of 6 of the sibling pairs (data
not shown).Shapiro et al
March 2016 ORIGINAL ARTICLESCSF T-tau and p-tau levels were modestly elevated relative
to control values and appeared to decline with increasing age,
so no relationship with disease progression was evident
(Figure 8; available at www.jpeds.com).
CSF opening pressure was normal (<20 cm water) in all
but 4 patients (data not shown). In these 4 patients, pressure
was normal in 2 or 3 out of 4 lumbar punctures. The highest
CSF opening pressure observed was 30 cm water, followed by
3 measurements between 20 and 25 cm.
Discussion
Our patients were sorted into 2 distinctive groups with
differing natural histories of cognitive and brain changes
and different disease cadences.3 Classifying patients with
MPS IIIA as RP or SP will enhance understanding of each pa-
tient’s disease stage. In our cohort, the one exception to accu-
rate classification by age of diagnosis1 was a patient
previously diagnosed with autism. This diagnosis, although
frequently observed in MPS IIIA,7 might have contributed
to the delayed recognition of MPS IIIA in this patient, who
was diagnosed at age 99months. Although by age >72months
he should have been classified as SP, his known severe muta-
tions classified him as RP. Both age of diagnosis and genetic
criteria are necessary to accurately classify patients, but the
latter will be limited by the frequent identification of new
mutations.
A positive trajectory of cognitive development was evident
in patients in the RP group who were aged <28 months at
baseline. A ceiling of development at 42-48 months was
observed in all but 1 patient in the RP group (Figure 1, A).
That patient, aged 45 months at baseline, acquired cognitive
skills over the first 6 months of the study, but lost significant
function by the 12-month follow-up visit. This slowing of
development between age 2 and 4 years in patients with
MPS IIIA has been described previously,5,32 and has been
reported in other untreated mucopolysaccharidosis disorders
as well.33-35 Given the very rapid development in typically
developing children between 2 and 4 years, evidence of
slowing at this age should prompt further diagnostic studies.
Disease progression has been described as slowing of
speech/language acquisition (phase 1), followed by a halt in
cognitive development with emerging behavioral abnormal-
ities (phase 2), and finally a loss of mobility progressing to a
vegetative state (phase 3).36 Median age of death is in the
second decade, usually due to neurologic disease.1,3,4 At base-
line, 2 patients of our cohort were in phase 1 (both diagnosed
early because of an affected sibling), and the other 23 patients
were in phase 2. Although designed to track this progression,
the FPSS4 lacked sensitivity to disease progression during the
second stage compared with the DQ.
When cognitive status was expressed as a DQ, all patients
in the RP group exhibited marked declines over 1 or 2 years
(Figure 1, B). Even in the youngest patients who had slower-
than-normal development, the BSID-III (used in all patients
in the RP group) had the requisite sensitivity for measuring
disease progression within a time interval that mightA Prospective Natural History Study of Mucopolysaccharidosis Tcorrespond to the duration of a therapeutic trial. The mean
loss of 15 DQ points over 1 year in children aged <6 years
is similar to findings reported in children with
mucopolysaccharidosis type IH (MPS IH), a loss of 15-20
points per year at age 1-3 years.32,33
Changes in cognition were closely mirrored by quantita-
tive neuroimaging findings. Brain atrophy and characteristic
perivascular spaces have been reported clinically,37,38 but
based on quantitative volumetrics, the consistent declines
in cortical gray matter volume starting at age 30 months
in patients in the RP group demonstrated a close association
with rate of cognitive decline (Figure 3, B). This atrophy was
accompanied by a compensatory increase in ventricular
volumes (Figure 5). White matter volumes were less
dramatically affected.
Volumetric analysis was not possible in the baseline MRI
scans in the 2 youngest patients, owing to a lack of gray mat-
ter–white matter contrast resulting from early changes in
gray matter water content and lack of myelination.39 Gray
matter growth to age 9 years with a small decline thereafter
and continued growth in white matter through adolescence
have been shown in typical development.40,41 Thus, our find-
ings of steep declines in gray matter volume represent gross
pathological changes associated with MPS IIIA. The primacy
of gray matter volume loss suggests that cognitive decline is
associated with loss or damage to cortical neurons. The
finding that a quantitative measure of brain structure is asso-
ciated with neurocognitive assessment points to the validity
of the latter as a clinical measure of disease progression in
this patient population.
Liver and spleen volumes were approximately double the
predicted normal volume for both the RP and SP phenotypes
(Figure 6).17,18 Although not usually diagnosed clinically,
this finding suggests that volumetric analysis could be a
useful treatment response marker.
Not surprisingly, CSF HS, CSF T-tau and p-tau, and urine
GAG levels were abnormally elevated. Nonetheless, in
contrast to cognitive and neuroimaging measures, there
was no relationship between these disease-associated bio-
markers and disease progression. Data from animal studies
suggest that MPS III is a “tauopathy.” 42,43; however,
although there were equivocal elevations in CSF T-tau and
p-tau levels, these were not useful markers of disease progres-
sion. Our data suggest age-related declines in these markers,
as may be observed physiologically in early life.44
The present study presents a composite picture of the pro-
gression of MPS IIIA over the course of childhood. Although
the fact that individual children were followed only for up to
2 years may be considered a limitation of the study, the pro-
spective design, together with the striking conformance of the
individual patient trajectories to the overall pattern, suggest
that this study represents an accurate picture of the long-
term natural history of this disease.
In conclusion, we found that cognitive decline, as
measured by DQ and cortical gray matter volume, is a sensi-
tive marker of disease progression in MPS IIIA. The consis-
tent declines in as little as 1 year suggest that these variablesype IIIA 285
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with RP MPS IIIA. The finding that developmental arrest oc-
curs around age 4 years suggests the importance of therapeu-
tic interventions before this stage to confer the greatest
benefit. Similar to MPS IH, for which early treatment with
hematopoietic cell transplantation benefits cognition,45
treatment should be instituted in children before the onset
of steep cognitive decline and brain atrophy. Unlike in
MPS IH, however, in MPS IIIA diagnosis is usually delayed
beyond this period, owing to the lack of apparent physical
features. Treatment with protein and gene replacement46 is
imminent, and once available, earlier diagnosis will be
crucial. This leads inevitably to considerations of newborn
screening and increased awareness by community practi-
tioners of the possibility of neurometabolic disease in chil-
dren with developmental delay. n
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Figure 4. A,White matter volumes by age for the RP and SP groups. B,White matter volume by DQ for the RP and SP groups.
Imputed values are for the same subjects as for gray matter volumes. All volumes were converted from cubic millimeters to
milliliters.
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Figure 5. CSF volumes in ventricles by age for the RP and SP groups.
Figure 6. Liver and spleen size relative to normal controls by
age based on percentage of normal and based solely on the
first reading for each patient.
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Figure 8. A, CSF T-tau protein levels and B, CSF T-tau and p-tau protein levels over time for the RP and SP groups compared
with controls.
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Table II. Control CSF HS levels
Age group
0-27 d 1-23 mo 2-11 y 12-18 y
Number, total 24 52 41 31
Number below LLoQ (%) 0 0 13 (44%) 27 (87%)
Minimum, mM 0.229 0.248 <0.251 <0.300
Maximum, mM 0.463 0.648 0.443 0.426
LLoQ, lower limit of quantitation.
HS levels were measured by tandem mass spectrometry in deidentified CSF samples collected
from children without MPS IIIA, obtained from the National Children’s Medical Center bio-
repository. Samples were assayed from the following age groups: birth to 27 days (24 samples),
1-23 months (52 samples), 2-11 years (41 samples, of which 44% were below the LLoQ), and
12-18 years (31 samples, of which 87% were below the LLoQ). The increasing frequency of
samples with HS levels below the LLoQ with increasing age suggests age-related declines
in CSF HS levels. The maximum level observed was 0.648 mM in a child in the 1-23 month
age group.
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